Summary
Transgene SA (Transgene) is a biopharmaceutical company that focuses on the discovery and development of immunotherapies in the areas of cancer and infectious diseases. The company’s lead clinical stage programs include TG4010, which is intended for the treatment of non small cell lung cancer and PexaVec, for liver cancer. It also has various other programs in clinical and pre clinical development including TG4001, for HIV positive cancers; TG1050, for chronic hepatitis B; and TG6002, for glioblastoma. The company has a presence in the US and China. Transgene is headquartered in Illkirch Graffenstaden, France.
Transgene SA (TNG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Transgene SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Transgene SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Transgene SA, Medical Devices Deals, 2010 to YTD 2016 10
Transgene SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Transgene SA, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Jennerex Biotherapeutics Raises US$21.6 Million In Venture Financing 13
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 14
Partnerships 16
Transgene Enters into Agreement with Merck and Pfizer 16
Transgene and SillaJen Amends Agreement 17
Transgene Enters Into Co-Development Agreement With Ligue nationale contre le cancer For Anticancer Biotherapies 18
Tianjin Tasly Forms Joint Venture With Transgene 19
Licensing Agreements 20
Transgene Enters Into Licensing Agreement With Ascend Biopharma For TG1042 20
Vivalis Enters Into Licensing Agreement With Transgene For Vaccines 21
ISA Pharma Enters Into Licensing Agreement With Transgene 22
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 23
Jennerex Enters Into Licensing Agreement With Transgene For JX-594 25
Transgene To Enter Into License Agreement For An Experimental Cancer Antibody 27
Transgene Enters Into Option Licensing Agreement With Novartis 28
Crucell Enters Into Licensing Agreement With Transgene 30
Equity Offering 31
Transgene to Raise USD52.61 Million in Rights Offering of Shares 31
Transgene Completes Rights Offering Of Shares For US$62.4 Million 33
Transgene Completes Private Placement of Shares for up to USD27.44 Million 35
Transgene Completes Rights Offering For US$228 Million 37
Asset Transactions 39
Advanced BioScience Labs Acquires Production Asset of Transgene 39
Acquisition 40
SillaJen Completes Acquisition Of Jennerex For US$150 Million 40
Transgene SA - Key Competitors 42
Key Employees 43
Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Tables
Transgene SA, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Transgene SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Transgene SA, Deals By Therapy Area, 2010 to YTD 2016 9
Transgene SA, Medical Devices Deals, 2010 to YTD 2016 10
Transgene SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Jennerex Biotherapeutics Raises US$21.6 Million In Venture Financing 13
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 14
Transgene Enters into Agreement with Merck and Pfizer 16
Transgene and SillaJen Amends Agreement 17
Transgene Enters Into Co-Development Agreement With Ligue nationale contre le cancer For Anticancer Biotherapies 18
Tianjin Tasly Forms Joint Venture With Transgene 19
Transgene Enters Into Licensing Agreement With Ascend Biopharma For TG1042 20
Vivalis Enters Into Licensing Agreement With Transgene For Vaccines 21
ISA Pharma Enters Into Licensing Agreement With Transgene 22
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 23
Jennerex Enters Into Licensing Agreement With Transgene For JX-594 25
Transgene To Enter Into License Agreement For An Experimental Cancer Antibody 27
Transgene Enters Into Option Licensing Agreement With Novartis 28
Crucell Enters Into Licensing Agreement With Transgene 30
Transgene to Raise USD52.61 Million in Rights Offering of Shares 31
Transgene Completes Rights Offering Of Shares For US$62.4 Million 33
Transgene Completes Private Placement of Shares for up to USD27.44 Million 35
Transgene Completes Rights Offering For US$228 Million 37
Advanced BioScience Labs Acquires Production Asset of Transgene 39
SillaJen Completes Acquisition Of Jennerex For US$150 Million 40
Transgene SA, Key Competitors 42
Transgene SA, Key Employees 43
Transgene SA, Other Locations 44
Transgene SA, Subsidiaries 44
List of Figures
Transgene SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Transgene SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Transgene SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Transgene SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Transgene SA, Medical Devices Deals, 2010 to YTD 2016 10
